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1 
Developing a safe and effective vaccine against severe acute respiratory syndrome corona virus 2 (SARS-2 
CoV-2) is crucial to ending the COVID-19 pandemic. But even during a global public health crisis, 3 
precautions and careful measures are necessary to ensure that new vaccines are safe for the population 4 
(Hotez et al. 2020).  5 
Accelerated vaccine development is being guided and supported by regulatory agencies like the EMA and 6 
the FDA. The WHO has also released the target product profile (TPP) to guide the development of future 7 
vaccines.  If the necessary safety and efficacy endpoints are met, the first licensed vaccine candidate should 8 
be available at the beginning of 2021. More than 320 different SARS-CoV-2 vaccine candidates are in 9 
development on a variety of vaccination platforms (Le et al. 2020; LSHTM 2020). Eight of these are 10 
currently being tested for efficacy trials in several thousands of people in high incidence countries.  11 
Vaccine design has been hampered by the limited quality and quantity of immunological data on SARS-12 
CoV-2 (Vabret et al. 2020). Researchers must identify the immune correlates of protection and the 13 
durability of immune responses to create an effective vaccine. They need to determine also the risk-benefit 14 
ratio of vaccination in different populations (e.g., elderly immunocompromised person, recovered cases, 15 
and those as yet unexposed). 16 
Researchers working to accelerate SARS-CoV-2 vaccination development have inferred answers to many 17 
of these questions based on data from past coronavirus epidemics (SARS-CoV and MERS-CoV) that 18 
caused severe respiratory syndromes  (Ahmed et al. 2020; Vabret et al. 2020). But it is tricky to determine 19 
the portion of the virus that should be included in vaccine formulations to balance efficacy and safety. The 20 
SARS-CoV spike protein, for example, is highly immunogenic, but it may increase antibody-dependent 21 
enhancement that might exacerbate lung disease in people reexposed to the virus (Hotez et al. 2020; Iwasaki 22 
and Yang 2020). Researchers do not know if the primary immune response against SARS-CoV-2 or its 23 
vaccine will exacerbate secondary immune response, so this question must be answered by clinical studies. 24 
Efficacy and safety are not the only important criteria. Vaccine candidate production must also be scalable. 25 
Production of authorized vaccines from raw materials can take 6 to 36 months to come to market (Plotkin 26 
et al. 2017), and a delay can drastically increase the number of infected people and the toll that preventive 27 
measures take on a country’s economy. Vaccine development and production must thus be expedited. 28 
Therefore, it is important to select the adequate vaccine platform to accelerate vaccine development. 29 
Although traditional vaccines (inactivated, life attenuated and subunit vaccines) are now safe and effective 30 
at a low cost per dose, they have several disadvantages during development: it is hard to scale up production 31 
processes, and setting up new manufacturing facilities takes several years to build. Thus, satisfying the 32 
global vaccine demand using traditional vaccine technologies could take two to three years. Newer versatile 33 
vaccination technologies (like vector-based vaccines and nucleic acids vaccines) may be faster and cost-34 
efficient. For example, nucleic acids vaccination technologies may dramatically decrease development 35 
costs and production, making it easier to scale up during a pandemic (Kis et al. 2018). Validated 36 
manufacturing facilities stand ready to produce nucleic acid vaccines. However, we must be cautious about 37 
these technologies because no nucleic acid vaccines for humans are yet on the market.  38 
2 
Furthermore, there is a multitude of challenges facing routine vaccination. Who will get the vaccine, and 39 
how will the vaccination program be implemented? The disease has rapidly spread across the globe, with 40 
more than 30 million affected (Dong et al. 2020). The pandemic has resulted in substantial direct and 41 
indirect economic losses.  Pharmaceutical companies have made enormous investments for vaccine 42 
development. With the tremendous demand and the limited supply for the first batch of vaccines, the basic 43 
principles of the market economy would be unethical to follow. High-income countries, which have high 44 
purchasing capacities, may gain better access to the vaccines, just as the current access to medical supplies 45 
and drugs for Covid-19. Similarly, within a country, a disparity in access might occur. The elderly 46 
population, who are considered mainly as economic dependents but face a higher risk of dying, would 47 
benefit more from the vaccines compared to the income earners who consist mostly of the middle-age 48 
group. Ideally, vaccination strategies should be focused first on the more vulnerable populations and those 49 
working on the frontlines of the healthcare system to lower the burden of the disease.  50 
In the race for a vaccine, multiple products are needed to meet the enormous global demand. Speeding up 51 
the development of new vaccines against SARS-CoV-2 is important, but ensuring safety and efficacy in 52 
clinical trials. Future vaccines must ensure the scalability, an adequate price for sustainable investment, and 53 
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